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Barrett’s esophagus is a condition in which the normal squamous lining of the esophagus has been replaced by columnar epithelium
containing intestinal metaplasia induced by recurrentmucosal injury related to gastroesophageal reflux disease. Barrett’s esophagus
is a premalignant condition that can progress through a dysplasia-carcinoma sequence to esophageal adenocarcinoma. Multiple
endoscopic ablative techniques have been developed with the goal of eradicating Barrett’s esophagus and preventing neoplastic
progression to esophageal adenocarcinoma. For patients with high-grade dysplasia or intramucosal neoplasia, radiofrequency
ablation with or without endoscopic resection for visible lesions is currently the most effective and safe treatment available. Recent
data demonstrate that, in patients with Barrett’s esophagus and low-grade dysplasia confirmed by a second pathologist, ablative
therapy results in a statistically significant reduction in progression to high-grade dysplasia and esophageal adenocarcinoma.
Treatment of dysplastic Barrett’s esophagus with radiofrequency ablation results in complete eradication of both dysplasia and of
intestinal metaplasia in a high proportion of patients with a low incidence of adverse events. A high proportion of treated patients
maintain the neosquamous epithelium after successful treatment without recurrence of intestinal metaplasia. Following successful
endoscopic treatment, endoscopic surveillance should be continued to detect any recurrent intestinal metaplasia and/or dysplasia.
This paper reviews all relevant publications on the endoscopic management of Barrett’s esophagus using radiofrequency ablation.
1. Introduction
Barrett’s esophagus (BE) is a premalignant condition inwhich
the normal squamous lining of the esophagus is replaced by
columnar epithelium containing intestinal metaplasia (IM),
induced by recurrent mucosal injury related to gastroe-
sophageal reflux disease [1].
Patients with BE are at increased risk of develop-
ing esophageal adenocarcinoma (EAC), a cancer that has
increased nearly sixfold over the last three decades and is
associated with a poor, less than 20%, 5-year survival rate [2].
Malignant degeneration of BE is gradual: from nondys-
plastic IM to low-grade dysplasia (LGD), to high-grade
dysplasia (HGD), and eventually progressing to inva-
sive cancer. Nondysplastic BE shows a very low risk of
malignant transformation with annual incidence of 0.33%;
therefore, endoscopic therapies should not be applied
[3].
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Recent data demonstrate that, in patients with BE and
LGD, ablative therapy results in a significant reduction of
progression to HGD or EAC [4, 5].
High-grade dysplasia or intramucosal cancer (IMC)
necessitates intervention and endoscopic eradication therapy
is the procedure of choice [6].
Endoscopic treatments for BE aim to eliminate Bar-
rett’s epithelium, subsequently replaced by normal squamous
epithelium. Two distinct endoscopic approaches have been
widely used. The first is the complete endoscopic mucosal
resection (EMR) of the BEmucosa.The other approach is the
ablation of the BE mucosa by using a variety of techniques
including photodynamic therapy, argon plasma coagulation
(APC), and, more recently, radiofrequency ablation (RFA).
The ablative therapy aims at elimination of BE by induc-
ing superficial tissue necrosis whereby damaged tissue is
subsequently replaced by normal squamous mucosa.
Radiofrequency ablation has become the ablative treat-
ment of choice in the management of dysplastic BE [6].
Endoscopicmucosal resection and RFA have both proven
to be effective in the eradication of dysplasia and intestinal
metaplasia in BE; however, adverse events are significantly
more frequent after complete EMR [7].
Radiofrequency is administered by using the Halo system
(Barrx Medical, Sunnyvale, Calif), which provides high
frequency alternating current to the mucosa with the aim
of ablating neoplastic mucosa to allow regrowth of normal
squamousmucosa. Reduction in rate of progression to cancer
with RFA have been demonstrated in randomized controlled
trials in HGD and LGD [4, 8].
However, many patients with HGD or IMC have nodu-
larity in their BE segment and EMR is commonly performed
to remove these nodular areas before treatment with RFA [6].
The aim of this review is to summarize results of all
important recent publications on this topic to answer relevant
clinical questions in order to evaluate the benefit and harm of
this therapy.
2. Method for Radiofrequency Ablation
This technique requires a specific catheter to apply the
radiofrequency ablation to the mucosa. Several sizes of
catheters are available, depending on the dimension of the
area that needs treating. The Halo 360 (Barrx Medical,
Sunnyvale, Calif) is a balloon-based catheter that delivers
high-energy pulse to the esophageal lining resulting in a
circumferential burn. This system consists of a high power
energy generator, a sizing balloon catheter, and balloon-based
ablation catheters with different outer diameters. The sizing
balloon is used to select the recommended size of the Halo
360.The ablation catheter consists of a noncompliant balloon
with a 3 cm long bipolar electrode on its outer surface and
available in five outer diameter sizes. Radiofrequency energy
is delivered through the electrodes over the balloon resulting
in circumferential superficial tissue destruction. The RFA
energy is directed uniformly to a depth of 0.5mm.
The Halo 90, Halo 90 Ultra, and Halo 60 probe catheters
may be used to treat focal areas of Barrett’s esophagus.These
probe catheters are attached to the distal end of the endoscope
and can be used to treat selected areas of the mucosa rather
than the whole circumference.
Recently, a new device was introduced to eliminate the
need for multiple endoscope insertions. Indeed, the new
Barrx! channel RFA endoscopic catheter delivers radiofre-
quency ablation through the working channel of a flexi-
ble endoscope, helping to simplify and reduce procedure
time.
3. Treatment Efficacy
3.1. Low-Grade Dysplasia. There is considerable uncertainty
regarding the natural history of LGD within BE. Expert
pathology review is important to accurately define patients
risk of progression and determining which patients would
benefit from treatment. After expert pathology review, 50%
to 85% of patients initially diagnosed with LGD may be
downstaged to nondysplastic BEwith an associated lower risk
of neoplastic progression, not requiring treatment [26, 27].
Recent data have shown that, when LGD is confirmed, the
annual risk of developing HGD/EAC is 9.1% [28]. A similar
high progression rate was seen in the original clinical trial
of radiofrequency ablation for dysplastic BE in which 14% of
patients in the sham treatment arm developed HGD at one
year of follow-up [8].
For patients with a confirmed diagnosis of LGD, RFA
is becoming more and more accepted as a therapeutic
option to prevent neoplastic progression [6]. Moreover, cost-
effectiveness analyses showed that RFA may be both more
effective and less expensive compared to surveillance alone
for confirmed and stable LGD [29].
The effectiveness of RFA in eradicating dysplasia ranges
from 61.5% to 100%, whereas the success of eradication of IM
ranges from 61.5% to 91% (Table 1) [4, 5, 8–16]. In particular,
with the exception of the study by Okoro et al. that reported
lower rates, all other studies reported eradication rates >90%
for LGD and >77% for IM. In the AIM Dysplasia Trial,
eradication of LGD was achieved in 90.5% of cases in the
ablation group at the end of 12 months, and the rate of
complete eradication of intestinal metaplasia (CE-IM) was
81% [14].
Sharma et al. evaluated RFA in 39 patients with LGD and
achieved complete eradication of dysplasia (CE-D) and CE-
IM in 95% and 87% of cases, respectively, with no cases of
neoplastic progression, at a median follow-up of 2 years [10].
Phoa et al., in a randomized trial comparing ablation ver-
sus surveillance, showed a complete eradication of dysplasia
and intestinal metaplasia in 92.6% and 88.2% [4].
A recent multicenter study confirmed that endoscopic
ablation has potential benefit over endoscopic surveillance in
the management of referred patients with LGD diagnosed by
an expert pathologist [5]. This study represents the largest
study to date to demonstrate the effectiveness of RFA for
LGD in routine practice [5]. The estimated cumulative risk
of progression to HGD or EAC within 3 years was 2.9% in
the RFA group versus 33.0% in the surveillance group, and
mucosal nodularity and multifocal dysplasia were found to
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be independent predictors for progression to HGD or EAC
[5].
Follow-up studies have demonstrated that a high percent-
age of subjects with LGD maintain CE-D and CE-IM after
treatment.
In a follow-up study, Shaheen et al. demonstrated dura-
bility of RFA with eradication of LGD and metaplasia in 98%
of cases at the end of a 2-year follow-up after ablation therapy
[13].
During the follow-up phase of their trial, Phoa et al.
reported that CE-D was maintained in 62 out of 63 (98.4%)
patients receiving ablation and CE-IM was maintained in 54
out of 60 patients (90.0%) [4].
In a nationwide, multicenter registry of patients treated
with RFA, one-fifth of patients, with a mean of 2.4-year
follow-up, had recurrent BE and likelihood for recurrence
was not influenced by pretreatment dysplasia [30].
3.2. High-Grade Intraepithelial/Intramucosal Cancer. Endo-
scopic therapy is a well-established treatment for more
advanced dysplasia, given the high rate of progression to EAC
in HGD [31].
The patients with intramucosal cancer can be managed
endoscopically given their low risk of local lymph node
involvement, whereas patients with lesions invading deep
into the submucosa should be considered for esophagectomy
[32].
Endoscopic therapy consists in EMRof visible lesions and
ablation of any residual BE [6]
Radiofrequency has proven to be very effective also for
eliminating BE with HGD and IMC.
The effectiveness of RFA in eradicating HG dysplasia
ranges from 74.4% to 100%, and the success of eradication of
IM ranges from 41% to 100% (Table 2) [8, 10–25].
In the AIMDysplasia Trial, CE-D was achieved in 81% of
cases in the ablation group at the end of 12months follow-up,
and the rate of CE-IM was 74% [8].
Van Vilsteren et al. showed a complete eradication of
dysplasia andmetaplasia in 96% (21 out of 22) of patients with
BE containing HGD/IMC and visible abnormalities treated
with focal EMR followed by RFA [20].
Haidry et al. analyzed data from a large series of patients
in the UK who underwent RFA for BE-related neoplasia [21].
Complete eradication of dysplasia was achieved in 81% of the
ablation group and CE-IM in 62%, while only 3% of cases
developed invasive cancer at 12months after treatment [21].
Several studies have addressed factors related to unsuc-
cessful RFA treatment in patients with HGD.
A prospective multicenter study demonstrated that poor
regression of BE 3 months after the first treatment is a
predictor of failure to achieve CE-D/CE-IM, requiring more
treatment sessions and a longer treatment period [33].
Another study identified incomplete mucosal healing
between treatment sessions as an independent predictor of
incomplete eradication of IM [15].
Length of Barrett’s segment, uncontrolled acidic reflux,
and size of hiatal hernia also seem to be associated with
increased failed therapy [16, 34].
Furthermore, recurrence of BE following complete erad-
ication should be considered.
Orman et al. in a systematic review with meta-analysis
found an IM recurrence rate of approximately 13%, whereas
dysplasia and EAC occurred in 0.9% and 0.7%, respectively,
over 1.5 years [35].
Pasricha et al. investigated the rate of recurrence of IM
after successful CE-IM in a multicenter registry of patients
treated with RFA, and of the 1634 enrolled, 334 (20%) had
recurrence of IM and the likelihood for recurrence was
associatedwith increasing age, BE length, and non-Caucasian
race [30].
Other studies have reported recurrence rates of up to 33%
at 2-year follow-up [21, 36].
Recently, Cotton et al. described the location of biopsies
and EMR specimens positive for recurrence during endo-
scopic surveillance after RFA for BE [37]. Recurrence tended
to occur most often around the GEJ; therefore, random
biopsies specifically directed around the GEJ have the highest
yield [37]. In contrast, recurrence >1 cm proximal to the GEJ
was always related to endoscopically visible lesions [37].
An important reason to biopsy the proximal areas of
previously treated BE is the possibility of identifying per-
sistence of glandular epithelium beneath the new squamous
epithelium, known as buried BE. These buried glands could
lead to future neoplastic progression, and the risk of buried
BE after ablative therapy is an important concern for all
ablative techniques [38].
However, several studies have demonstrated that the
presence of buried glands in normal-appearing neosquamous
epithelium after RFA is rare [8, 12, 39, 40].
4. Comparative Data
Two RCTs of RFA versus only endoscopic surveillance in BE
showed that RFA had a high rate of complete eradication
of dysplasia and IM and decreased disease progression
compared with the control group [4, 8].
In the AIM Dysplasia Trial, 127 patients with dysplastic
BE in a 2 : 1 ratio were randomized to receive either RFA
(84 patients) or a sham procedure (43 patients) [8]. Among
all patients, regardless of the grade of dysplasia, complete
eradication of all intestinal metaplasia occurred in 77.4% of
the patients assigned to the RFA group, as compared with
2.3% of those assigned to the control group (푃 < 0.001)
[8]. Patients who were assigned to the control group were
more likely to have disease progression (16.3%) than were
those in the RFA group (3.6%, 푃 = 0.03) [8]. Among all
patients, regardless of the grade of dysplasia, significantly
more esophageal cancer cases developed in the control group
than in the RFA group (9.3% versus 1.2%, 푃 = 0.045) [8].
Phoa et al. in a randomized trial of RFA versus surveil-
lance enrolled 136 patients with a confirmed diagnosis of BE
with LGD [4]. Among patients in the RFA group, complete
eradication occurred in 92.6% cases of dysplasia and 88.2%of
intestinalmetaplasia, compared to 27.9% for dysplasia and 0%
for intestinal metaplasia among patients in the control group
(푃 < 0.001). Complications occurred in 19.1% of patients
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receiving RFA (푃 < 0.001) [4]. Radiofrequency ablation
compared to surveillance reduced the risk of progression to
HGD or EAC by 25.0% (1.5% versus 26.5%; 95% CI, 14.1%–
35.9%; 푃 < 0.001) and the risk of progression to EAC by 7.4%
(1.5% versus 8.8%; 95% CI, 0%–14.7%; 푃 = 0.03) [4]. Indeed,
this study underwent early termination due to superiority
of ablation compared to surveillance, since patients in the
ablation group were less likely than the control group to
progress to high-grade dysplasia or adenocarcinoma [4].
A retrospective study compared 65BE patients withHGD
or IMC treated with EMR and RFA for nodular disease and
104 patients treated with RFA alone for BE with nonnodular
disease; EMR and RFA achieved CE-D and CE-IM in 94%
and 88% of patients, respectively, compared with 82.7% and
77.6% of patients, respectively, in the RFA alone group (푃 =0.06 and 푃 = 0.13, resp.).The complication rates between the
two groups were similar (7.7% versus 9.6%, 푃 = 0.79) [41].
Van Vilsteren et al. compared the safety of stepwise
radical EMR versus focal EMR followed by RFA for complete
eradication of BE containing HGD/IMC [20]. Complete
eradication of dysplasia was achieved in 100% (25/25) of
patients in the EMR group and in 96% (21/22) of patients
in the EMR/RFA group; complete eradication of intestinal
metaplasia was achieved in 92% (23/25) of patients in the
EMR group and in 96% (21/22) of patients in the EMR/RFA
group [20]. However, the rate of posttreatment stenosis was
significantly higher in the EMR group (88%) compared with
EMR/RFA (푃 < 0.001) [20].
Radiofrequency ablation was also compared with photo-
dynamic therapy (PDT) in a consecutive series of patients
with BE [42]. Complete eradication of dysplasia was achieved
in 18/33 patients (54.5%) with PDT and in 47/53 patients
(88.7%) with RFA (푃 = 0.001) [42]. Comparing the results,
PDT was five times more costly than RFA and one patient in
the PDT group had an esophageal perforation, managed with
nonsurgical measures, while no perforation was seen with
RFA group [42].
5. Complications
Radiofrequency ablation has a lower complication rate com-
pared with complete EMR [7].
The most common complication associated with
esophageal RFA is posttreatment stricture formation with a
reported incidence up to 19% [4, 8, 10–16, 21–25].
Chest pain and dysphagia are commonbut usually resolve
spontaneously.
Hemorrhage has also been reported, although less com-
monly, while esophageal perforations are very rare with a rate
of less than 0.6% [43].
Radiofrequency after EMR could result in an increased
incidence of stricture formation.
Two studies compared the incidence of complications
between patients that underwent RFA after EMR or RFA
alone and found no difference in the rate of complications
between the two groups [14, 41].
However, a recent meta-analyses found the relative risk
for adverse events due to RFA to be about 4-fold higher
with EMR than without.The rate of esophageal strictures was
higher in the RFA plus EMR group (13.3%) compared to the
RFA alone group (5.1%) [43].
6. Conclusion
In conclusion, the use of RFA for the treatment of dysplastic
BE results in CE-D and CE-IM in a high proportion of
patients, with only few recurrences of IM after treatment and
low rates of adverse events. Both EMR and RFA have proven
to be effective treatments in the eradication of dysplastic BE,
although adverse events rates are significantly higher after
EMR. Finally, RFA with prior EMR of any nodular areas is
the endoscopic treatment of choice for high-grade dysplastic
BE.
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